UVA Cancer Center to Expand Use of Theraclion’s HIFU System in Cancer Treatment Research
01 Juin 2021 - 6:00PM
Business Wire
Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE, PEA-PME
eligible), an innovative company specialized in echotherapy
treatment (using High Intensity Focused Ultrasound or HIFU),
announces a phase-2 collaboration with the University of Virginia
Cancer Center. This extends the investigation of combining HIFU
with immunotherapy from late-stage to that of early-stage breast
cancer. If successful, such a protocol could open a new way for
treatment. An estimated 3.8 million women have a history of breast
cancer in the US1.
After an initial successful collaboration, the University of
Virginia (UVA) Cancer Center has extended the use of Theraclion’s
world-class technology to a phase-2 investigation. This further
collaboration includes the sale and servicing for 3 years of their
current Echopulse system used for research in breast tumour
treatment. It includes un-limited usage for 3 years to support all
investigations.
Patrick Dillon, Associate Professor in the department of
Oncology and David Brenin, Professor in diseases of the breast and
Chief of the Division of Breast and Melanoma Surgical Services at
University of Virginia, said: “We look forward to working in
collaboration with Theraclion to conduct research on the efficacy
of the combination of focused ultrasound ablation and immune
therapy as a potential treatment for patients with breast cancer.
We are excited to continue to work to improve the efficacy,
precision, and safety of this potential approach.”
Promising clinical study in progress
UVA researchers have investigated the potential application of
Theraclion’s technology, using focused ultrasound (FUS) to overcome
the limitation of the accessibility of immunotherapies to tumors
due to poor T cell infiltration and mechanisms of adaptive
resistance is known. Based on positive results on murine mammary
carcinoma2, a pilot clinical study has been initiated3 to evaluate
the use of HIFU combined with pembrolizumab in patients with
metastatic breast cancer. The study tested the hypothesis that FUS
thermal ablation can serve as an auto-vaccine for treatment of BRCA
with immunotherapy on patients with confirmed metastatic or
unresectable breast cancer. Final results should be shared in few
months, but the study has shown promising properties of HIFU on
breast tumors. This has encouraged the UVA research team to further
investigate the potential benefits of HIFU.
New study focused on treatment of early-stage breast
cancer
A new study4 has been designed to test the use of focused
ultrasound ablation, low-dose gemcitabine (a chemotherapy) and the
combination of focused ultrasound ablation plus low-dose
gemcitabine in patients with early-stage breast cancers. They will
be testing the effects of each of these regimens on cells in the
immune system. They hypothesize that the combination of focused
ultrasound ablation and gemcitabine will decrease myeloid-derived
suppressor cells and will increase T cell activity. They also
hypothesize that focused ultrasound ablation and low-dose
gemcitabine will be safe and will result in non-inferior surgical
completion rates and tumor margin assessments. “The cooperation
established with the University of Virginia in their investigations
should benefit breast cancer patients and pave the way for a new
era of treatment offering an alternative to surgery” said David
Caumartin, CEO of Theraclion.
This study will test the use of focused ultrasound ablation,
low-dose gemcitabine (a chemotherapy) and the combination of
focused ultrasound ablation plus low-dose gemcitabine in patients
with early-stage breast cancers. They will be testing the effects
of each of these regimens on cells in the immune system. They
hypothesize that the combination of focused ultrasound ablation and
gemcitabine will decrease myeloid-derived suppressor cells and will
increase T cell activity. They also hypothesize that focused
ultrasound ablation and low-dose gemcitabine will be safe and will
result in non-inferior surgical completion rates and tumor margin
assessments.
About University of Virginia Cancer Center
The UVA Cancer Center is one of 71 centers in the US with
designation from the National Cancer Institute. US News & World
Report has ranked the UVA Medical Center as the No. 1 hospital in
Virginia and its cancer services among the top 10% in the United
States. It is designated as a Center of Excellence by the Focused
Ultrasound Foundation and is home to the first fully dedicated
focused ultrasound facility in the world. The center is renowned
for its research and development strategy and for its innovative
clinical trials.
About Theraclion
Theraclion has developed an innovative echotherapy solution
using High Intensity Focused Ultrasound for the treatment of
varicose veins, SONOVEIN®. The treatment solution, which obtained
CE marking in April 2019, is based on the leading-edge echotherapy
treatment expertise developed by Theraclion over years for
non-invasive ablation of breast fibroadenomas and thyroid nodules
using its ECHOPULSE® solution. Further improvements to the
ECHOPULSE technology are the foundation for SONOVEIN to provide the
only non-invasive ablation therapy for varicose veins. This
procedure allows for treatment without a catheter, chemical
injection, or incision. An operating room is not necessary, and the
treatment can be performed at a doctor’s offices or in clinics, as
well as in hospitals. Venous pathology is widespread worldwide and
generates around 5 million treatment procedures per year, according
to Millennium research Varicose Vein Device Market Study 2015.
Theraclion's technological solutions are based on high-tech
ultrasound medical devices that are precise and easy to use for
practitioners. Located in Malakoff, near Paris, Theraclion brings
together a team of 25 people, more than half of whom are dedicated
to R&D and clinical trials.
For more information, please visit the Theraclion website:
www.theraclion.com and the patient site:
https://echotherapie.com/echotherapy/
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
9695007X7HA7A1GCYD29
1 Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer
Statistics Review, 1975-2016. Bethesda, MD: National Cancer
Institute; 2019. Availble from seer.cancer.gov/csr/1975_2016/,
based on November 2018 SEER data submission, posted to the SEER web
site April 2019. 2 Perspectives on Recent Progress in Focused
Ultrasound Immunotherapy Natasha D. Sheybani and Richard J. Price 3
Focused Ultrasound Therapy to Augment Antigen Presentation and
Immune-Specificity of Checkpoint Inhibitor Therapy with
Pembrolizumab in Metastatic Breast Cancer Focused Ultrasound and
Pembrolizumab in Metastatic Breast Cancer - Full Text View -
ClinicalTrials.gov 4 Focused Ultrasound with Low-Dose Gemcitabine
to Augment Immune Control of Early-Stage Breast Focused Ultrasound
and Gemcitabine in Breast Cancer - Full Text View -
ClinicalTrials.gov
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210601005467/en/
Theraclion
David Caumartin Chief Executive Officer
david.caumartin@theraclion.com Tel : + 33 (0)1 55 48 90 70
Anja Kleber VP Marketing, Market Access & Sales Francophonia
anja.kleber@theraclion.com
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024